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ABSTRACT  
   
Development of effective therapeutic interventions for the treatment of mental 
health disorders has been a significant driving force in the search to understand the 
human brain.  Current treatments for mental health disorders rely on modulating 
neurotransmitter systems such as norepinephrine (NE), serotonin (5-HT), dopamine (DA) 
and γ-aminobutyric acid (GABA) to achieve clinically relevant relief of symptoms.  
While many medications are available to the clinician that individually target these neural 
systems, treatment often results in patients reporting unwanted side effects or 
experiencing incomplete relief. To counter this lack of treatment efficacy, further 
investigation of other avenues for achieving similar or better outcomes and potentially 
reach patients refractory to common therapies must be undertaken. One of these potential 
new target systems is the endogenous cannabinoid system (ECS), which is currently 
composed of cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).  These 
metabotropic seven transmembrane (7-TM) loop G-protein coupled receptors (GPCR) are 
responsible for mediating the effects of acute Cannabis ingestion as well as modulating 
several core functions of the nervous system including emotion, memory, and learning 
behavior.  Due ubiquitous expression of ECS proteins, there is broad overlap between 
brain regions that show high levels of receptor expression and those thought to be 
involved in the etiology of a range of mental health disorders including depression, 
anxiety and schizophrenia.  Consequently, modulation of cannabinoid receptor function is 
a novel and potentially clinically relevant mechanism for influencing the levels of other 
neuromodulators and neurotransmitters, such as dopamine, that are known to play crucial 
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roles in the progression of mental illness.  In addition, characterization of endogenous 
cannabinoids and cannabinoid receptors with respect to their normal physiological 
function and possible roles in pathophysiology may provide insight for the development 
of future ECS-based therapies.  
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CHAPTER 1 
INTRODUCTION 
 
Increasing awareness regarding the prevalence of mental health disorders has, 
over the course of the last three decades, occurred alongside dramatic advances in 
technology that have allowed investigation into the fundamental neurobiological 
mechanisms underlying these disorders1.  This work has resulted in a vast body of 
scientific knowledge seeking to address the physiological substrates that are responsible 
for the development and progression of mental health disorders, but it has not been easy 
to directly translate this knowledge into definitively effective therapies.  This problem of 
treatment efficacy is, at least in part, related to the highly stigmatized nature of our 
population’s perceptions concerning the nature of mental illness1.   This is exemplified by 
the fact that despite significant advances in the field of mental health research, less than 
50 percent of those suffering from depression receive adequate treatment1–3.  Many 
overlapping factors produce this lack of treatment efficacy, including social constructs 
and the physiological side effects of the pharmacological tools used in the course of 
treatment1–5.  Consequently, the search to find new molecules to alleviate the symptoms 
of mental health disorders while reducing the side effect profile of the drug(s) used is of 
the utmost importance.  Emerging lines of evidence point toward new treatment 
possibilities that are centered on modulation of the endogenous cannabinoid system 
(ECS) to exert their therapeutic effect.   
 Cannabis sativa is the most commonly used illicit drug worldwide6. With a deep 
history of Cannabis use among humans dating back millennia, it is only within the last 
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century that possession of any form of the Cannabis plant has become illegal7.  The 
primary psychotropic compound found within Cannabis is delta-9-terahydrocannabinol 
(∆9-THC) as shown in Figure 1 and table 1. This molecule produces euphoric sensations 
typically cited as part of the negative consequences of Cannabis ingestion6,8.  While this 
one substance is responsible for the illegality of Cannabis, there are hundreds of related, 
yet diverse compounds, known as phytocannabinoids, found within the resin of Cannabis 
sativa that have unknown mechanisms of action9–11.   These various cannabinoid 
molecules must be individually studied for potential therapeutic effects that could be 
produced without the psychotropic side effects of THC.  Likely, there are components of 
the plant that have previously gone unnoticed, which could provide new avenues for 
modulation of the human central nervous system and the treatment of disease7.  Over the 
past decade, there has been significant academic interest in exploring the full breadth of 
the neuromodulatory effects produced by the constituent components of Cannabis sativa.   
This resurgence has paralleled the emergence of a new population of individuals that 
ingest Cannabis regularly to treat a variety of medical conditions, often with the 
recommendation of a medical professional12–14. However, without firm scientific 
evidence regarding the efficacy of many of the purported medical benefits claimed by 
individuals within this community, these patients cannot receive the same level of care 
received by patients undergoing conventional therapy. To address this disparity in 
knowledge regarding the delivery of efficacious treatment, evidence of the medical 
properties of Cannabis must be collected through rigorous scientific inquiry to 
adequately treat this new population of patients.   Consequently, there exists great 
potential for development of new pharmacological therapies from the plethora of 
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phytocannabinoid compounds that could act on targets in the central nervous system 
(CNS)8–10.  Many of these compounds have been isolated but remain largely 
uncharacterized in terms of their physiological and pharmacological effects in humans.  
Rigorous investigation of these phytocannabinoids could reveal new modulatory 
mechanisms that may prove efficacious in the treatment of mental health disorders.  In 
addition, characterization of endogenous cannabinoids and cannabinoid receptors with 
respect to their normal physiological function and possible roles in pathophysiology may 
provide insight for the development of novel ECS modulation-based therapies. 
 
 CB1 CB2 
Agonist 
CP 55,940, Arachidonoyl- 
Glycerol (2-AG), 
JWH-015, JWH-051, JWH-
133, CP 55,940 
Partial Agonist 
Anandamide (AEA), 
∆9-Tetrahydrocannabinol 
(THC, Dronabinol),  
WIN 55,212-2, 
 
WIN 55,212-2, Anandamide 
(AEA),  ∆9-
Tetrahydrocannabinol,  
2-Arachydonyl- 
Glycerol (2-AG) 
 
Antagonist/Inverse 
Agonist 
SR 141617A, LY 320315,  
AM 251 
SR144528, AM630 
 
Table 1 – Cannabinoid Receptor Ligands 
Various synthetic, endogenous, and plant derived ligands of cannabinoid receptors 1 and 
2 grouped based on their activity profile at each receptor target.  As shown above, 
cannabinoids derived from plant sources are primarily partial agonists at the cannabinoid 
receptors and have additional activity at other receptors that are not considered members 
of the cannabinoid family.  
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Figure 1 – Molecular Structure of Endogenous and Synthetic Cannabinoids 
Delta-9-Tetrahydracannabinol (d9-THC) is thought to be the primary psychoactive 
constituent of Cannabis sativa and is known to act at CB1 receptors to produce a range of 
effects on cognition, emotion as well as physiological functions such as cardiac output.  
Anandamide and 2-Arachidonoylglycerol are the primary endogenous cannabinoids 
which are derived from lipid precursors found in the membranes of cells throughout the 
body.  Rimonabant is a CB1 receptor inverse agonist that was marketed for a short time 
but withdrawn after negative effects including suicidal ideation were observed in patients 
receiving it to control weight gain and JWH-133 is a potent and highly selective CB2 
receptor agonist used to research the endogenous cannabinoid system.     
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Studies investigating the role of the ECS in mediating mental health disorders as 
well as healthy physiological processes is still quite young relative to investigation of 
other neuronal signaling systems.  Most of the evidence from human studies has focused 
on the effects of THC with recent animal studies of cannabinoid (CB) receptor 
psychopharmacology making use of newly synthesized and highly specific targeted 
ligands to better understand this receptor system.  To facilitate understanding of this 
system, a short overview of ECS anatomy and physiology is presented below with 
additional consideration given to potential new cannabinoid receptors as well as other 
targets of endogenous cannabinoid ligands. Each subsequent section addresses a major 
mental health disorder including affective disorders, psychotic disorders, and anxiety 
disorders along with a discussion of how the ECS could potentially be involved in each 
and how they could be impacted by the development of new therapies targeting the ECS.  
Specifically, the pathological features of the underlying neural physiology in each of 
these disorders will be discussed.  It is from this perspective of dysfunctional neural 
physiology that recent discoveries regarding the endogenous cannabinoid system can be 
applied toward the development of novel therapeutics strategies targeting patients 
suffering from mental health disorders.   
 
The Endogenous Cannabinoid System 
 The symptoms associated with mental health disorders are widely believed to be 
the result of deleterious changes in the underlying functionality of molecular pathways 
mediating neuronal communication within the central nervous system1.  Aberrant patterns 
of neuronal activity are present in the brain, it can lead to alterations in the behavioral 
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profile that characterizes each of us as individuals.  A variety of neurotransmitter receptor 
proteins are expressed in neural tissue, forming functionally nested control systems that 
perform sensory integration and guide motor output.  These systems interact in a variety 
of ways to regulate cellular communication through the release of neurotransmitter 
signaling molecules such as acetylcholine, glutamate, and gamma amino butyric acid 
(GABA), which represent some of the most well characterized signaling systems15–18.  
Cannabinoid receptors are another subclass of this protein signaling system that is 
defined by these proteins’ ability to bind molecules derived from the Cannabis sativa 
plant, as well as other synthetic cannabinoid molecules15.  Unfortunately, research into 
the endogenous cannabinoid system has lagged far behind that of other receptor families 
due to the precarious nature of the legal situation surrounding sources of cannabinoid 
ligands.  With the advent of synthetic cannabinoid molecules, significant strides have 
been made in understanding the anatomy and physiology of this receptor class.  Much of 
this work has demonstrated that the endogenous cannabinoid system like other 
neuromodulatory systems is widely expressed and thus represents a novel and powerful 
means of targeting the underlying pathological properties of neural networks in patients 
suffering from mental health disorders19–21.  
The endogenous cannabinoid system is currently composed of cannabinoid 
receptor 1 (CB1) and cannabinoid receptor (CB2) with recent evidence heavily 
suggesting a possible third member currently designated G-protein receptor 55 
(GPR55)15,18,22.  These CB receptors are widely distributed throughout mammalian tissue 
and early immunohistochemistry studies have revealed CB1 receptors are the most 
abundant receptors in neural tissue, with evidence of neural CB2 only emerging late this 
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past decade15,23.  Previously, CB2 had been considered the peripheral CB receptor since it 
is expressed at high concentrations within the spleen and is found on B cells, NK cells, 
and lymphocytes23.   Neuroanatomical localization of the CB1 receptor has shown 
abundant protein expression in the neo-cortex, hippocampus, amygdala, striatum, and 
midbrain nuclei15–20,24.  The CB1 receptor has been found primarily on presynaptic 
axonal terminals (Figure 2) with some expression observed on post synaptic cell bodies.    
All the CB receptor proteins are members of the super family of seven transmembrane 
loop G-protein coupled receptors (GPCR’s) bound to an inhibitory internal enzymatic 
complex (Gi/o) that is released upon receptor activation15,25.   Activation of CB1 initiates 
a signaling cascade inhibiting adenylyl cyclase and presynaptic N p/q type calcium 
channels, in addition to activating MAP kinase proteins and presynaptic inwardly 
rectifying potassium channels15,25,26.  This signaling cascade results in cannabinoid 
mediated retrograde synaptic plasticity. This occurs through synthesis of cannabinoids in 
the post synaptic density and is dependent upon the arrival of presynaptic signals.  These 
cannabinoids, produced after signal arrival, diffuse away from the synapse and act on the 
terminal itself, ultimately influencing its long-term vesicular output15,25.  The effects of 
CB2 activation are very similar to that of CB1 but have not been entirely functionally 
characterized within brain tissue23,27,28.  CB receptors have also been identified on 
astrocytes, with the demonstration that these receptors are functionally relevant on both 
neurons and glia27.  This evidence regarding CB mediated neuron to glia communication 
speaks further to their relevance as a robust signaling system within the CNS. 
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Figure 2 – ECS Modulation of Excitatory Synaptic Activity 
Release of excitatory neurotransmitter glutamate from presynaptic terminal binds to post 
synaptic receptors causing depolarization of the membrane and induces the synthesis of 
both 2-AG and AEA, depending on the specific cellular population. On-demand synthesis 
of 2-AG and AEA leads to retrograde control of excitation through activating CB1R 
causing inhibition of adenylate cyclase via Gi and subsequent decreased neurotransmitter 
release from the presynaptic terminal, which is thought to aid in the prevention of 
excitoxicity during periods of sustained input activity.  Similar effects can be observed at 
synaptic terminals containing other transmitters, such as GABA, which means 
cannabinoids serve as a means of controlling short term synaptic plasticity.  
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There are several endogenous molecules that serve as ligands at cannabinoid 
receptor binding sites, all of which possess a molecular motif making them lipid soluble.  
The solubility of these compounds allows them to serve as long-term messengers that can 
perpetuate retrograde signals, which persist in the membrane far after the passage of an 
action potential.  This longevity is part of the therapeutic potential of these compounds, 
as their effects tend to have significant duration due to the lipophilic structure of these 
ligands15,18.  This elongation of action creates a broader window of therapeutic action and 
reduces the chance of lethal overdose.  Anandamide (AEA, Figure 3) is the most well 
documented endogenous cannabinoid and is locally synthesized from ethanolamine and 
arachidonic acid precursors in an on-demand fashion based on recent levels of cellular 
activity8,15,18.   This molecule and its relative compounds are produced through hydrolysis 
of N-arachidonoyl phosphatidyl ethanolamine (NAPE) by phospholipase D.   Synthesis is 
based on intracellular levels of calcium and cyclic AMP (cAMP).  While basal 
anandamide concentrations are kept low, the endocannabinoid 2-arachidonoyl glycerol 
(2-AG) is found in much higher concentrations throughout the brain.   The primary 
pathway for synthesis of 2-AG as shown in Figure 4, employs the hydrolysis of 
phosphatidylinositol by phospholipase C (PLC) and diacylglycerol lipase (DAG).   
Binding of these natural ligands is differential, with anandamide serving as a low efficacy 
agonist at both receptors whereas 2-AG has high levels of efficacy at both receptor sites.  
Along with their unique synthesis pathways, anandamide and 2-AG have separate 
degradation processes with anandamide being broken down by fatty acid amine 
hydrolases (FAAH) and 2-AG by monoacylglycerol lipase (MAG)8,15,18,29–32. 
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Figure 3 – Biosynthetic pathway of Anandamide 
Enzymatic biosynthesis of the endogenous cannabinoid N-Arachidonoylethanolamine 
(Anandamide, AEA) from phosphatidylethanolamine precursor and subsequent 
hydrolysis by Fatty Acid Amine Hydrolase.   
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Figure 4 – Biosynthesis of 2-Arachidonoylglycerol 
One of the pathways regulating the enzymatic biosynthesis of 2-arachidonoylglycerol (2-
AG) from one of its phospholipid precursors, which is a process that is heavily dependent 
upon levels of intracellular calcium. 
 
 
Manipulation of the ECS can be performed using direct agonists or antagonists of 
CB receptors and concentrations of endogenous ligands can be altered by 
pharmacologically interfering with enzymatic degradation pathways12–15,33.  
Phytocannabinoids that act at CB receptors include ∆9-THC,  ∆8-THC, cannabinol, and 
cannabidiol with the former facilitating the primary psychoactive effects of acute 
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Cannabis ingestion and the latter maintaining little psychoactive capacity.  These natural 
ligands are not known for their high selectivity and only with the advent of synthetic 
compounds has localization been clearly performed6,8–11.  An example of this abundant 
cross selectivity is the transient receptor potential vanilloid 1 receptors (TRPV1), which 
is activated by many of the same molecules that trigger CB receptor activation34,35.  This 
indicates the presence of a highly complex lipid signaling system that is dependent upon 
the local composition of lipids in the cellular membrane, along with dependence on the 
local receptor expression profile.  Together, these two variables interact to produce an 
averaged CB signal that can have dramatic effects on synaptic responses to incoming 
depolarization.  As a result, high endocannabinoid densities can be found at synapses 
after periods of sustained cellular firing36.  These lipids in the cellular membrane act on 
CB1 receptors and produce a physical constant that regulates potassium and calcium 
currents through the synapse15,25,32,37–39.  This inhibitory regulation of synaptic current 
explains the effects of strong CB agonists where application can result in reduced motor 
coordination, mood elevation, memory storage deficits, and increased appetite15,39–42.  
With this effect on appetite in mind, blockade of the CB1 receptor has been investigated 
as a method for treating obesity.  Models in mice have shown lean body phenotype is 
associated with high levels of endogenous cannabinoids. Also, weight loss among obese 
rats with administration of CB1 antagonists has been observed43.  The CB1 antagonist 
SR141716A (Rimonabant) was developed for this purpose in humans and was briefly 
released into some market’s where patients in clinical trials and subsequently following 
release of the drug experienced increases in anxiety, depression, and suicidal ideation, 
likely due to the distribution of CB1 receptors in the basal ganglia (Table 2).  After 
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considering the effects of this antagonist, it was removed from the market even though 
the drug was effective at achieving reductions in weight44.   
 The ECS provides an optimal target for therapeutic intervention regarding mental 
health disorders. The ubiquitous expression of CB proteins includes many of the key 
systems targeted by existing therapies, such as selective serotonin reuptake inhibitors 
(SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)6,13,15–18,45–55.  This is 
illustrated by the fact that ∆9-THC, when applied alone and in moderate doses, produces 
an antidepressant effect on human subjects 41,56.  Synthetic encapsulated ∆9-THC is 
available as a schedule 3 drug in the United States known as Dronabinol for the treatment 
of nausea, vomiting and other symptoms associated with chemotherapy treatment57.  The 
recent discovery of neural CB2 receptors suggests this family of receptors is still largely 
unexplored in the brain and further inquiry should be conducted to identify possible new 
therapeutic targets27,28,58.  Neurophysiological characterization of other receptor systems 
has demonstrated how differences in receptor density and localization provide key insight 
into how that specific neurotransmitter system participates in the general process of 
cognition.  Further exploratory studies investigating the interactions between CB1 and 
CB2 are required to elucidate how this system functions at a molecular and cellular level.   
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CHAPTER 2 
MENTAL HEALTH DISORDERS AND THE ENDOGENOUS CANNABINOID 
SYSTEM 
 
Affective Disorders 
 One of the most prolific classifications of mental health disorders are those that 
disrupt processing of emotional stimuli, known as affective or mood disorders1,2.  Within 
this classification, we find smaller groups with distinct symptoms including bi-polar 
disorder (BP), major depressive disorder (MDD), dysthymic disorder, and cyclothymic 
disorder.  Approximately 9.5% of American adults aged 18-44 have experienced an 
affective disorder from one of these categories in the past 12 months; BP and MDD 
comprise most cases and will be the focus of this discussion1.  The neuroanatomical 
substrates underlying the expression of affective disorders have been the subject of great 
debate within the mental health community. There are large bodies of evidence pointing 
toward improper of storage and excessive focus on negatively biased memories as a key 
pathological feature observed in depression1,2,59–63.   Patients suffering from affective 
disorders often have decreased neuronal activity in the dorsal frontal cortex as well as 
dysfunctional activity with cell loss observed in the hippocampus and amygdala1,60,64.  To 
counter pathological activity in these brain regions, modern antidepressant drugs have 
been designed to target specific proteins involved in the uptake of serotonin and 
norepinephrine1–5.   This eventually leads to an increase in the basal levels of these 
neurotransmitters found in the synapses of neurons across the brain.  Patients experience 
elevated dopamine release due to these alterations in basal serotonin and norepinephrine 
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levels and generally experience elevated mood as a result.  Although these 
pharmacological interventions are effective, especially when coupled with behavioral 
treatments, there remains a large population that does not respond to conventional 
treatment alone1,2,4,5.  This treatment-resistant group could benefit from altering the basal 
norepinephrine and serotonin levels using a different intermediary than conventional 
drugs. Manipulation of the ECS could serve as a means for providing this therapeutic 
modulation of the neural substrates underlying the disease pathology.    
 
Major Depressive Disorder (MDD) 
 Diagnosis of MDD generally occurs after the administration of a variety of tests 
from the DSM-V to determine whether there is a disruption in the processing of 
emotional cues.  Tests are routinely performed by a psychologist or psychiatrist, with 
additional observation of symptoms such as fatigue, lowered mood, suicidal ideation, 
lack of appetite, and disruption of normal sleeping patterns.  Broad fluctuations in 
symptomology with this disorder can lead to difficulties in diagnosis, as patients can 
sometimes be hesitant to initially consult a specialized physician concerning their 
condition1.  This may be observed by the increasing number of patients diagnosed with 
MDD by their family or general practitioner instead of a mental health professional.  
Conventional treatments for MDD modulate serotonin and norepinephrine, increasing 
dopaminergic tone and generally resulting in relief of depressive symptoms1,2.     
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Bipolar Disorder 1 and 2 
 Patients suffering from bipolar disorder, formerly referred to as manic-depression, 
experience symptoms characterized by cyclic fluctuations between periods of manic 
happiness and deep depression61,62.  About 2.6% of American adults have been diagnosed 
or were bipolar within the past twelve months1.  The large changes in mood are often 
disruptive to relationships and can interfere with a patient’s ability to maintain steady 
work.  The distinction between the two forms of the disorder is primarily determined by 
examining the extent of the manic episodes, as bipolar 2 patients generally do not 
manifest with as potent manic symptoms.  Those suffering from bipolar 2 disorder can 
often be confused with a person suffering intermittent depression and diagnosis must be 
performed with respect to long term symptomology.  Lithium is one of the most common 
mood stabilizers and has gained popularity in treating bipolar disorder even though it has 
a very small therapeutic window1,2,61,62.   
 
 
The ECS and Affective Disorders 
 Investigating the ECS could enhance our ability to treat mental health disorders in 
the future by providing alternative molecular routes for modulating serotonin and 
norepinephrine.  For example, CB1 receptors have been identified in the raphe nucleus of 
the midbrain, which is a major nucleus containing noradrenergic cell groups53,54. These 
noradrenergic cells project axons throughout the brain to provide modulation of 
glutamate and GABA at specific sites including cells of the amygdala, striatum, and 
forebrain.  In models of depression, there are deficits in noradrenergic signaling that 
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ultimately result in decreased dopaminergic tone and can result in negatively biased 
mood60.  In addition, there are abundant CB1 receptors expressed in the amygdala, a 
major neural substrate of emotional processing, as well as the hippocampus, which 
participates in memory storage and retrieval20,21,41,55,64–69.  This indicates that CB 
receptors are likely involved in the emotional coding of memories and could potentially 
present a method for modulating aberrant ideation on negative emotions.  To this effect, 
mice overexpressing CB2 receptors have a phenotype that leaves them less vulnerable to 
negative stressors 47.  In contrast, human studies have shown that individuals with certain 
variations of the CB1 gene have a higher potential for being resistant to pharmacological 
treatment for depression and therefore could be more at risk if depression occurs69.  
Taken together, these lines of evidence suggest that the ECS is involved in the processing 
of emotional memories and could potentially provide a novel means of countering the 
deleterious behavior associated with mental illness70.    
In addition to its action with pharmacological plasticity, the CB1 receptor has recently 
been implicated in the neurogenesis of inhibitory neurons within the hippocampus40,46,53.  
This finding is significant because perturbations in memory formation are observed in 
affective disorders along with deficits in hippocampal cell growth.  Conventional 
therapies that targets serotonergic systems have also been shown to induce neurogenesis, 
which has led to the development of the neurogenesis hypothesis regarding depression71–
73.  This extends the role of cannabinoids in memory beyond molecular plasticity to a new 
level that includes developmental plasticity in response to environmental interactions.  
This evidence suggests that the ECS could be involved in regulating emotional memory 
and this may explain why we see antidepressant effects with THC administration.    
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Schizophrenia and Psychotic Disorders 
 Approximately 1.1% of the US adult population currently suffers from a 
psychotic disorder of some kind, which is relatively low when compared with other 
mental health disorders1,74.  The chronic, severe nature of the symptoms associated with 
this disorder makes it particularly challenging to treat and can have drastic effects on a 
patient’s long-term health.  The manifestation of psychosis varies based on the individual, 
but generally produces behavioral, emotional, and cognitive symptoms often 
characterized by somatosensory hallucinations, inabilities to execute planning, and erratic 
control of emotion56,57,75,76.  Three major classes of symptoms referred to as positive, 
negative and cognitive have been developed to describe the range of behaviors observed 
in patients diagnosed with schizophrenia.  The positive symptoms reported by patients 
include hallucinations and delusions that can affect all motor and sensory systems with 
varying levels of intensity.  Negative symptoms incorporate those that have to do with 
disruption of the patient’s emotional state, like that observed within affective disorders 
which can sometimes complicate the diagnosis of schizophrenia as it is confused with 
other less severe disorder initially58,67,77–79.  Lastly, the cognitive symptoms of 
schizophrenia can be subtle, with slight perturbations to higher order executive functions 
that can often only be detected with the administration of highly specialized tests by a 
mental health professional.  Among these categories, there is a large degree of variation 
in expression of the disorder that is likely due to subtle variations in underlying 
pathological features1,80,81.  In the face of this variation, some progress has been made in 
recognizing common elements between individuals with evidence pointing toward 
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deficits in limbic dopamine signaling and frontal cortical hypo-activity contributing to the 
disorder7,31,39,82.   
 
 
The ECS and Schizophrenia 
 The involvement of the ECS in the emergence of schizophrenia has been highly 
debated and there is little controlled research involving human subjects to adequately 
infer therapeutic relationships.  There is evidence to suggest that Cannabis use can 
improve cognitive function in certain patients with schizophrenia83–85.  This concept is 
contrary to much of the evidence in the schizophrenia research community, where many 
report Cannabis as a potential factor that can precipitate the emergence of 
psychosis58,68,74,78.  While conflicting results exist, some studies have shown that 
Cannabis abuse can exacerbate psychotic symptoms in patients already predisposed to 
schizophrenia.  Many of these studies rely upon correlations drawn from interviews of 
clinical populations suffering from schizophrenia that have either recently used Cannabis  
or have a history of past recreational use7,83,86–89.  The inherently broad array of 
symptoms experienced by schizophrenic patients makes designing studies to investigate 
this population more difficult than studies involving other mental health disorders.  These 
studies are often subject to confounding factors in the form of selection bias and recall 
bias, which means they need to be carefully evaluated before conclusions can 
extrapolated to the wider human population. Several studies using post-mortem human 
brain tissue demonstrate alterations in CB receptor localization and density, though with 
conflicting outcomes with some demonstrating increased density of CB1 and others 
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demonstrating no significant difference or reduced CB1 expression compared to control 
samples. Since there are few adequate mouse models that can fully replicate the 
symptoms of schizophrenia, our progression towards understanding the underlying neural 
physiology of schizophrenia has been slower than for other mental health disorders90.  
The few models that do exist in rodents have shown that agonism of the ECS can reduce 
the severity of the negative symptoms of schizophrenia but has little effect on the positive 
symptoms of the disorder91,92 . Black et. al. suggests that antagonism of CB1 with co-
administration of anti-psychotics improves cognitive function and reduces the side-effect 
profiles of anti-psychotics. An example of this is observed in schizophrenia patients who 
use Cannabis and also display higher levels of success in measures of psychomotor speed 
when compared with those who do not use Cannabis64,83,93. As discussed, prior evidence 
suggests the pathophysiology of schizophrenia may be linked to deficits in limbic 
dopamine signaling. Thus far, CB receptors 1 and 2 have been reported in high density in 
limbic and para-limbic areas and are involved in dopamine signaling, suggesting a 
possible link between dysfunction of the ECS and schizophrenia and highlighting the 
need for further investigation into this system for possible therapeutic manipulation. 
 
 
Anxiety/Fear Disorder 
 Anxiety is a psychophysiological state characterized 
by somatic, emotional, cognitive, and behavioral components, which affects roughly 40 
million Americans above 18 years of age1,2,70,93.  In a clinical setting, humans are 
diagnosed with anxiety disorders through the professional administration of tests from the 
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Diagnostic and Statistical Manual of Mental Disorders (DSM-V)70.  Based upon certain 
criteria, clinicians can separate the observed behaviors into a variety of subtypes of 
anxiety including Generalized Anxiety Disorder (GAD), Panic Disorder, Post Traumatic 
Stress Disorder (PTSD), Obsessive Compulsive Disorder (OCD), or a Phobia of some 
kind.  While anxiety, is to some extent relevant for survival of an organism in the face of 
natural stressors, its persistence beyond situational arousal is generally considered 
pathological94.  
 The etiology of anxiety disorders is unclear. It is known changes occur to the 
primary modulators of synaptic transmission including shifts in serotonin, nor-
epinephrine, and dopamine release72,80,95,96. These same neuromodulators are associated 
with depression and many hypothesize these disorders are intertwined, with treatments 
for both disorders overlapping heavily67,80. For example, studies of mood in humans and 
rodents have shown severe or long-lasting stress can change the anatomical distribution 
of neuromodulators in the brain and therefore affect behavior. Other investigations have 
shown individuals with certain anxiety disorders possess variations in neuroanatomical 
structures identified to play a crucial role in controlling memory and mood76,82,97. 
Moreover, environmental factors, such as trauma or a major life-altering event, could 
trigger the emergence of anxious behavior in those who have an inherited susceptibility98. 
Treatment for anxiety usually consists of combined behavioral therapy with 
pharmacological manipulation using classical drugs including benzodiazepines, 
buspirone, selective serotonin or nor-epinephrine reuptake inhibitors, and older tricyclic 
antidepressants70,80.  These options have had limited success as their efficacy is highly 
patient dependent and the side effects are often intolerable, leading to discontinuation of 
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therapy.  This suggests pharmacotherapies with better tolerability and broader efficacy 
must be developed, which is where the ECS is poised to play a crucial role7,84,85,99.  
 
 
The ECS and Anxiety 
  Cannabinoid receptors have been identified in many regions that are associated 
with anxiety, such as the amygdala, hippocampus, ventromedial forebrain, and 
periaqueductal grey86–88.  However, interpretation of this localization and its effects on 
anxiety in rodents has been difficult.  Many studies of the effects of cannabinoids on 
anxiety in mammals show varied outcomes, which can often be attributed to differences 
in dose, drug, or experimental design. There have been major attempts to parallel 
classifications of behavior in humans to models of anxiety in rodents with limited success 
based upon the paradigm and behavior of interest.  Measures of time spent in open versus 
enclosed environments, such as the elevated plus maze, have been used to great effect in 
the study of anxiety in rodents84. This method is based on the logic that rodents have 
evolved in an environment where enclosed spaces are relatively safe and anxiety free, and 
the open spaces represent the opposite.  Therefore, when an animal is placed in such a 
maze, the time spent out in the open and time spent in enclosed spaces can be reported as 
a ratio representing the anxiety level of the animal.   Even though great attempts to 
standardize these methods have been made, interpretation of rodent behavior is still 
somewhat subjective.  Clearly this situation requires remediation and further study should 
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be dedicated to focusing the lens of experimentation on standardized models of anxiety in 
rodents. 
  There are several means of altering tone within the ECS, including direct 
agonism, direct antagonism, and blocking enzymatic pathways of cannabinoid 
degradation to increase endogenous levels.  Studies using direct agonists of the ECS 
including Delta -9- THC, WIN55-212,2, anandamide, and others have shown that CB1 is 
responsible for the primary psychoactive effects associated with Cannabis ingestion. The 
nature of the behavioral effects of these drugs on anxiety is biphasic, with low doses 
producing anxiolytic effects and anxiogenic effects emerging when high doses are 
administered89,89,90,100. In a mouse model of anxiety, the behavioral traits associated with 
anxiety can be ameliorated by injection of CB1 agonist into the dorsal hippocampus.  
Additionally, blockade of CB1 results in an anxiogenic response when CB1 antagonist 
AM251 is directly injected into the core of the amygdala or when it is administered 
systemically. The synthetic compound URB597 is an inhibitor of FAAH and when 
administered with anandamide can produce anxiety, but if either is given alone, they 
produce anxiolytic effects89.  Since CB1 is psychoactive, its use to treat anxiety is 
clouded due to its side effects, such as euphoria during the initial stages of blood plasma 
saturation. To this end, CB2 has been investigated as a potential anxiolytic target since it 
does not possess the psychoactive properties associated with CB1 activation.  Studies of 
CB2 and behavior have shown rodents with higher CB2 expression are resistant to 
anxiety and have differential responses to benzodiazepines, likely due to changes in 
GABAergic tone.  Studies of this receptor and its relationship to anxious behavior are 
still limited and must be further explored before any strong conclusions can be drawn.  
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Since there is evidence the ECS interacts with many different modulatory systems, 
including current anxiety treatments, exploration of this receptor family could open a new 
taxonomy of lipid-like drugs92.   
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CHAPTER 3 
FUTURE INSIGHTS FOR THERAPEUTIC DEVELOPMENT 
 
The ubiquitous expression of CB receptors on cells in the brain presents a wide 
array of possibilities for altering neuronal activity and potentially treating pathological 
activity8,24,54,73.  Given the complexity of the ECS, further studies must be conducted to 
establish a baseline for comparison to models of disease.  Genetic knock-out mice have 
been one of the most supportive tools in recent efforts to understand the cannabinoid 
system as they lack CB receptor expression.  Behavioral assessment of the mice under 
application of various cannabinoids will allow the assessment of specific 
pharmacological activity for various ligands.  These results can then be translated into 
human trials used to formally test the potential of the compound.  Currently, no clinical 
trials can be performed using herbal derivatives of Cannabis even though the material 
likely contains potent modulators of psychological state.  Future research aimed at 
isolating specific herbal ligands for behavioral and pharmacological evaluation in animal 
models is the next step.  In addition, combinations of cannabinoids should be studied 
together due to the moderate selectivity of many ligands.  It is likely that what is 
observed with Cannabis is due to the mixture of cannabinoids found within the plant 
itself and not due to specific ligands such a THC alone101. The phytocannabinoids within 
Cannabis have already undergone evolutionary development through coexistence with 
mammals and are likely an important reservoir of information for the understanding and 
modulation of our endogenous neurological systems. 
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 The lipophilic nature of cannabinoid ligands confers them an inherent advantage 
over other molecules because they can traverse the blood brain barrier (BBB) and are 
incorporated into the cell membrane.  Embedded within and free to move along the plane 
of the plasma membrane, cannabinoid ligands probabilistically interact with CB 
receptors.  The probability of CB receptor activation scales with the density of ligands in 
the membrane is a complex value due to the partial activity of many molecules at these 
receptors42.  This suggests that drugs designed to target cannabinoid receptors will have a 
longer half-life and have a high therapeutic index as the hydrophobic nature of the 
molecule reduces the chances of overdose.  Properties such as these represent key 
advantages of cannabinoids that could be beneficial in scenarios where current treatments 
carry risks of abuse and non-compliance, such as in bipolar disorder or schizophrenia.   
 The emergence of incredibly powerful genetic and molecular tools, including 
fluorescent probes, has provided the tools to study the very foundations of mental health 
in our own cells.  To truly understand the physiological mechanisms of the ECS, we must 
look beyond cultural stigmas to envision new medical frontiers wherever they may 
present. From the modest research conducted thus far, it is apparent the ECS plays a 
crucial role in normal neurophysiology and in many functions that we consider core 
elements of our human existence, such as memory and emotion. It is also probable that 
the ECS is involved in mediating symptoms of mental health disorders, and dysfunction 
of the ECS may even be involved in the pathogenesis of mental health disorders. With 
current research so focused on determining the underlying mechanisms and potential 
therapeutic opportunities of mental health disorders, it is enormously short-sighted to 
ignore such an integral and robust signaling system. Investigating the ECS, especially in 
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conjunction with other neural signaling systems will likely provide a more 
comprehensive understanding of normal neurophysiology and pathophysiology, as well 
as present novel techniques for modulating the symptoms of mental health disorders. 
  28 
REFERENCES 
 
1.  Kessler R. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV 
Disorders in the National Comorbidity Survey Replication. Archives of General 
Psychiatry. 2005;62(6):617. 
 
2.  Belmaker RH, Agam G. Major depressive disorder. The New England journal of 
medicine. 2008;358(1):55-68. doi:10.1056/NEJMra073096 
 
3.  Bschor T, Adli M. Treatment of depressive disorders. Deutsches Ärzteblatt 
international. 2008;105(45):782-792. doi:10.3238/arztebl.2008.0782 
 
4.  Inoue T, Sasaki K, Boku S, et al. Sertraline treatment of patients with major 
depressive disorder who failed initial treatment with paroxetine or fluvoxamine. Progress 
in neuro-psychopharmacology & biological psychiatry. 2012;38(2):223. 
doi:10.1016/j.pnpbp.2012.04.001 
 
5.  Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive 
disorder. Cochrane database of systematic reviews (Online). 2012;12:CD009138. 
 
6.  Soyka M. Cannabinoids and mental health. Schmerz (Berlin, Germany). 
2003;17(4):268-273. doi:10.1007/s00482-003-0226-x 
 
7.  Busquets-Garcia A, Puighermanal E, Pastor A, Torre R de la, Maldonado R, 
Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and 
anxiety-like responses. Biological psychiatry. 2011;70(5):479-486. 
doi:10.1016/j.biopsych.2011.04.022 
 
8.  Straiker A, Hu SS-J, Long JZ, et al. Monoacylglycerol Lipase Limits the Duration 
of Endocannabinoid-Mediated Depolarization-Induced Suppression of Excitation in 
Autaptic Hippocampal Neurons. Molecular pharmacology. 2009;76(6):1220. 
doi:10.1124/mol.109.059030 
 
9.  Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and 
JWH073, commonly found in “Spice” herbal blends, are potent and efficacious CB(1) 
cannabinoid receptor agonists. European journal of pharmacology. 2011;659(2-3):139. 
 
10.  Ross RA. Anandamide and vanilloid TRPV1 receptors. British journal of 
pharmacology. 2003;140(5):790-801. doi:10.1038/sj.bjp.0705467 
 
11.  Adamczyk P, Miszkiel J, McCreary AC, Filip M, Papp M, Przegaliński E. The 
effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine 
addictive behavior in rats. Brain research. 2012;1444(0):45-54. 
doi:10.1016/j.brainres.2012.01.030 
  29 
12.  Morgan NH, Stanford IM, Woodhall GL. Functional CB2 type cannabinoid 
receptors at CNS synapses. Neuropharmacology. 2009;57(4):356-368. 
doi:10.1016/j.neuropharm.2009.07.017 
 
13.  Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of 
a protective system? Progress in lipid research. 2011;50(2):193-211. 
doi:10.1016/j.plipres.2011.01.001 
 
14.  Straiker A, Mackie K. Cannabinoids, electrophysiology, and retrograde 
messengers: challenges for the next 5 years. The AAPS journal. 2006;8(2):E272-E276. 
doi:10.1007/BF02854897 
 
15.  Hampson RE, Miller F, Palchik G, Deadwyler SA. Cannabinoid receptor 
activation modifies NMDA receptor mediated release of intracellular calcium: 
Implications for endocannabinoid control of hippocampal neural plasticity. 
Neuropharmacology. 2011;60(6):944-952. doi:10.1016/j.neuropharm.2011.01.039 
 
16.  Walsh S, Mnich K, Mackie K, Gorman AM, Finn DP, Dowd E. Loss of 
cannabinoid CB.sub.1 receptor expression in the 6-hydroxydopamine-induced 
nigrostriatal terminal lesion model of Parkinson’s disease in the rat. Brain research 
bulletin. 2010;81(6):543. doi:10.1016/j.brainresbull.2010.01.009 
 
17.  El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of Δ 9-
tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. 
Pharmacology, Biochemistry and Behavior. 2010;95(4):434-442. 
doi:10.1016/j.pbb.2010.03.004 
 
18.  Mackie K. Understanding cannabinoid psychoactivity with mouse genetic models. 
PLoS biology. 2007;5(10):e280. doi:10.1371/journal.pbio.0050280 
 
19.  Trillou CR, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cannabinoid 
receptor knockout in mice leads to leanness, resistance to diet-induced obesity and 
enhanced leptin sensitivity. International journal of obesity. 2004;28(4):640-648. 
doi:10.1038/sj.ijo.0802583 
 
20.  Kelly DL, McMahon RP, Huestis MA, et al. Effects of the cannabinoid-1 receptor 
antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: 
a randomized, double-blind, pilot study. Journal of clinical psychopharmacology. 
2011;31(1):86-91. doi:10.1097/JCP.0b013e318204825b 
 
21.  Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation 
of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a 
mechanism for receptor cross-talk? Molecular pharmacology. 2005;67(5):1697-1704. 
doi:10.1124/mol.104.006882 
  30 
22.  Lau T, Schloss P. The cannabinoid CB 1 receptor is expressed on serotonergic 
and dopaminergic neurons. European journal of pharmacology. 2008;578(2):137-141. 
doi:10.1016/j.ejphar.2007.09.022 
 
23.  Kleijn J, Wiskerke J, Cremers TIFH, Schoffelmeer ANM, Westerink BHC, Pattij 
T. Effects of amphetamine on dopamine release in the rat nucleus accumbens shell region 
depend on cannabinoid CB1 receptor activation. Neurochemistry international. 
2012;60(8):791. doi:10.1016/j.neuint.2012.03.002 
 
24.  Häring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid 
receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience. 
2007;146(3):1212-1219. doi:10.1016/j.neuroscience.2007.02.021 
 
25.  Schulze DR, Carroll FI, McMahon LR. Interactions between dopamine 
transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology. 
2012;222(3):425-438. doi:10.1007/s00213-012-2661-9 
 
26.  Lane DA, Chan J, Fitzgerald ML, Kearn CS, Mackie K, Pickel VM. Quinpirole 
elicits differential in vivo changes in the pre- and postsynaptic distributions of dopamine 
D^sub 2^ receptors in mouse striatum: relation to cannabinoid-1 (CB^sub 1^) receptor 
targeting. Psychopharmacology. 2012;221(1):101. doi:10.1007/s00213-011-2553-4 
 
27.  Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine 
neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. 
Neuropharmacology. 2005;48(8):1105-1116. doi:10.1016/j.neuropharm.2005.03.016 
 
28.  Ferreira SG, Teixeira FM, Garção P, et al. Presynaptic CB(1) cannabinoid 
receptors control frontocortical serotonin and glutamate release–species differences. 
Neurochemistry international. 2012;61(2):219. 
 
29.  Oropeza VC, Mackie K, Bockstaele EJV. Cannabinoid receptors are localized to 
noradrenergic axon terminals in the rat frontal cortex. Brain research. 2007;1127(1):36-
44. doi:10.1016/j.brainres.2006.09.110 
 
30.  Carvalho AF, Bockstaele EJV. Cannabinoid modulation of noradrenergic circuits: 
Implications for psychiatric disorders. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry. 2012;38(1):59-67. doi:10.1016/j.pnpbp.2012.01.008 
 
31.  Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor 
systems in neural emotional learning circuits: implications for schizophrenia and 
addiction. Cellular and Molecular Life Sciences. 2006;63(14):1597-1613. 
doi:10.1007/s00018-006-6027-5 
 
  31 
32.  Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorectic 
effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behavioural 
pharmacology. 2003;14(8):573-582. doi:10.1097/01.fbp.0000104880.69384.38 
 
33.  Radbruch L, Nauck F. Review of cannabinoids in the treatment of nausea and 
vomiting. Schmerz (Berlin, Germany). 2004;18(4):306. 
 
34.  Atwood BK, Straiker A, Mackie K. CB₂: therapeutic target-in-waiting. Progress 
in neuro-psychopharmacology & biological psychiatry. 2012;38(1):16. 
 
35.  Hamilton JP, Gotlib IH. Neural Substrates of Increased Memory Sensitivity for 
Negative Stimuli in Major Depression. Biological psychiatry. 2008;63(12):1155-1162. 
doi:10.1016/j.biopsych.2007.12.015 
 
36.  Yu T, Guo M, Garza J, et al. Cognitive and neural correlates of depression-like 
behaviour in socially defeated mice: an animal model of depression with cognitive 
dysfunction. The International Journal of Neuropsychopharmacology. 2011;14(03):303. 
doi:10.1017/S1461145710000945 
 
37.  Mantere O, Suominen K, Leppämäki S, Valtonen H, Arvilommi P, Isometsä E. 
The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings from 
the Jorvi Bipolar Study (JoBS). Bipolar disorders. 2004;6(5):395-405. 
doi:10.1111/j.1399-5618.2004.00140.x 
 
38.  Miller K. Bipolar disorder: etiology, diagnosis, and management. Journal of the 
American Academy of Nurse Practitioners. 2006;18(8):368-373. doi:10.1111/j.1745-
7599.2006.00148.x 
 
39.  Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. 
Bipolar disorders. 2009;11(8):787-806. doi:10.1111/j.1399-5618.2009.00760.x 
 
40.  Samuels BA, Hen R. Neurogenesis and affective disorders. European Journal of 
Neuroscience. 2011;33(6):1152-1159. doi:10.1111/j.1460-9568.2011.07614.x 
 
41.  Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions 
throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol 
(Oxford). 2012;26(1):150-163. doi:10.1177/0269881111408459 
 
42.  Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of 
CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 
2002;159(4):379-387. doi:10.1007/s00213-001-0946-5 
 
43.  McLaughlin RJ, Gobbi G. Cannabinoids and emotionality: a neuroanatomical 
perspective. Neuroscience. 2012;204:134-144. doi:10.1016/j.neuroscience.2011.07.052 
  32 
44.  Katona I, Rancz EA, Acsady L, et al. Distribution of CB1 cannabinoid receptors 
in the amygdala and their role in the control of GABAergic transmission. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2001;21(23):9506-
9518. 
 
45.  Domschke K, Arolt V, Deckert J, et al. Cannabinoid receptor 1 (CNR1) gene: 
impact on antidepressant treatment response and emotion processing in major depression. 
European neuropsychopharmacology : the journal of the European College of 
Neuropsychopharmacology. 2008;18(10):751-759. doi:10.1016/j.euroneuro.2008.05.003 
 
46.  Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult 
hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. The 
Journal of clinical investigation. 2005;115(11):3104-3116. doi:10.1172/JCI25509 
 
47.  Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J. 
Depression-resistant endophenotype in mice overexpressing cannabinoid CB2 receptors. 
British journal of pharmacology. 2010;160(7):1773-1773. doi:10.1111/j.1476-
5381.2010.00819.x 
 
48.  Serra G, Fratta W. A possible role for the endocannabinoid system in the 
neurobiology of depression. Clinical practice and epidemiology in mental health : CP & 
EMH. 2007;3(1):25-25. doi:10.1186/1745-0179-3-25 
 
49.  Katona I, Sperlágh B, Maglóczky Z, et al. GABAergic interneurons are the targets 
of cannabinoid actions in the human hippocampus. Neuroscience. 2000;100(4):797-804. 
doi:10.1016/S0306-4522(00)00286-4 
 
50.  Katona I, Urbán GM, Wallace M, et al. Molecular composition of the 
endocannabinoid system at glutamatergic synapses. The Journal of neuroscience : the 
official journal of the Society for Neuroscience. 2006;26(21):5628-5637. 
doi:10.1523/JNEUROSCI.0309-06.2006 
 
51.  Katona I, Sperlagh B, Sik A, et al. Presynaptically Located CB1 Cannabinoid 
Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal 
Interneurons. Journal of Neuroscience. 1999;19(11):4544. 
 
52.  Mackie K, Katona I. Get stoned in GABAergic synapses. Nature neuroscience. 
2009;12(9):1081-1083. doi:10.1038/nn0909-1081 
 
53.  Wolf SA, Ullrich O, Kempermann G, et al. Cannabinoid receptor CB1 mediates 
baseline and activity-induced survival of new neurons in adult hippocampal 
neurogenesis. Cell communication and signaling : CCS. 2010;8(1):12-12. 
doi:10.1186/1478-811X-8-12 
 
  33 
54.  Clinical: Clinical Review - Schizophrenia. GP (London, England : 1994). 
2010:49. 
 
55.  Cuesta MJ, Ugarte MD, Goicoa T, Eraso S, Peralta V. A taxometric analysis of 
schizophrenia symptoms. Psychiatry research. 2007;150(3):245-253. 
doi:10.1016/j.psychres.2006.01.019 
 
56.  Freedman R. Neuronal Dysfunction and Schizophrenia Symptoms. The American 
Journal of Psychiatry. 2007;164(3):385-390. 
 
57.  Kendall T. Treating negative symptoms of schizophrenia. BMJ (Clinical research 
ed). 2012;344:e664. doi:10.1136/bmj.e664 
 
58.  Lodge DJ, Grace AA. Developmental pathology, dopamine, stress and 
schizophrenia. International Journal of Developmental Neuroscience. 2011;29(3):207-
213. doi:10.1016/j.ijdevneu.2010.08.002 
 
59.  Schwarcz G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol 
(dronabinol) can improve the symptoms of schizophrenia. Journal of clinical 
psychopharmacology. 2009;29(3):255. 
 
60.  Zuardi AW, Crippa JAS, Hallak JEC, Moreira FA, Guimarães FS. Cannabidiol, a 
Cannabis sativa constituent, as an antipsychotic drug. Brazilian journal of medical and 
biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade 
Brasileira de Biofísica .[et al]. 2006;39(4):421-429. 
 
61.  Metrik J, Kahler CW, McGeary JE, Monti PM, Rohsenow DJ. Acute Effects of 
Marijuana Smoking on Negative and Positive Affect. Journal of Cognitive 
Psychotherapy. 2011;25(1):31-46. doi:10.1891/0889-8391.25.1.31 
 
62.  Wilson N, Cadet JL. Comorbid mood, psychosis, and marijuana abuse disorders: 
a theoretical review. Journal of addictive diseases. 2009;28(4):309-319. 
doi:10.1080/10550880903182960 
 
63.  Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: 
impact on onset, course, psychopathology and outcomes. European Archives of 
Psychiatry and Clinical Neurosciences. 2002;252(2):86-92. doi:10.1007/s00406-002-
0366-5 
 
64.  Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of 
cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency 
of use. Schizophrenia research. 2007;96(1-3):169-184. doi:10.1016/j.schres.2007.08.006 
 
  34 
65.  Pierre JM. Psychosis Associated With Medical Marijuana: Risk vs. Benefits of 
Medicinal Cannabis Use. American Journal of Psychiatry. 2010;167(5):598-599. 
doi:10.1176/appi.ajp.201 0.09121762 
 
66.  Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: 
an epidemiological perspective. Australian and New Zealand Journal of Psychiatry. 
2000;34(3):468-468. doi:10.1046/j.1440-1614.2000.00736.x 
 
67.  Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of 
schizophrenia. Progress in neurobiology. 2010;90(3):285-326. 
doi:10.1016/j.pneurobio.2009.10.018 
 
68.  Spano MS, Fadda P, Frau R, Fattore L, Fratta W. Cannabinoid self-administration 
attenuates PCP-induced schizophrenia-like symptoms in adult rats. European 
Neuropsychopharmacology. 2010;20(1):25-36. doi:10.1016/j.euroneuro.2009.09.004 
 
69.  Black MD, Pichat P, Arad M, et al. AVE1625, a cannabinoid CB1 receptor 
antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in 
cognitive function and reduction of antipsychotic-side effects in rodents. 
Psychopharmacology. 2011;215(1):149-163. doi:10.1007/s00213-010-2124-0 
 
70.  Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological 
treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress 
disorder in primary care. International Journal of Psychiatry in Clinical Practice. 
2012;16(2):77-84. doi:10.3109/13651501.2012.667114 
 
71.  Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-
HT2A and dopamine D2 receptors in rat prefrontal cortex. Journal of 
Psychopharmacology. 2012;26(10):1333-1347. doi:10.1177/0269881112450786 
 
72.  Christianson JP, Ragole T, Amat J, et al. 5-hydroxytryptamine 2C receptors in the 
basolateral amygdala are involved in the expression of anxiety after uncontrollable 
traumatic stress. Biological psychiatry. 2010;67(4):339-345. 
doi:10.1016/j.biopsych.2009.09.011 
 
73.  Coulston CM, Perdices M, Tennant CC. The neuropsychology of cannabis and 
other substance use in schizophrenia: review of the literature and critical evaluation of 
methodological issues. The Australian and New Zealand Journal of Psychiatry. 
2007;41(11):869-884. doi:10.1080/00048670701634952 
 
74.  Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. 
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and 
clinical effects of current and future therapeutic agents. Molecular Psychiatry. 
2012;17:1206. 
  35 
75.  Jockers-Scherübl MC, Rentzsch J, Danker-Hopfe H, et al. Adequate antipsychotic 
treatment normalizes serum nerve growth factor concentrations in schizophrenia with and 
without cannabis or additional substance abuse. Neuroscience letters. 2006;400(3):262-
266. doi:10.1016/j.neulet.2006.02.056 
 
76.  Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related 
disorders. Acta Psychiatrica Scandinavica. 2011;124(4):250-261. doi:10.1111/j.1600-
0447.2011.01687.x 
 
77.  A G, F.M L, C.W G, et al. Cerebrospinal anandamie levels are elevatd in acute 
schizophrenia and are inversley correlated with psychotic symptoms. 
Neuropsychopharmacology. 2004;29:2108. 
 
78.  D’Souza DC, Sewell RA, Ranganathan M. Cannabis and 
psychosis/schizophrenia: human studies. European archives of psychiatry and clinical 
neuroscience. 2009;259(7):413-431. doi:10.1007/s00406-009-0024-2 
 
79.  Hamera E, Schneider JK, Deviney S. Alcohol, cannabis, nicotine, and caffeine 
use and symptom distress in schizophrenia. The Journal of nervous and mental disease. 
1995;183(9):559. 
 
80.  Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. 
Pharmacological treatment of anxiety disorders: Current treatments and future directions. 
Journal of anxiety disorders. 2012;26(8):833. doi:10.1016/j.janxdis.2012.07.009 
 
81.  Ashton CH. Adverse effects of cannabis and cannabinoids. British journal of 
anaesthesia. 1999;83(4):637. 
 
82.  Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate 
anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific 
agents. Behavioural Pharmacology. 2004;15(4):299. 
doi:10.1097/01.fbp.0000135704.56422.40 
 
83.  Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in 
mood and anxiety disorders. Behavioural pharmacology. 2005;16(5-6):315-331. 
doi:10.1097/00008877-200509000-00005 
 
84.  Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like 
response in mice. Pharmacological reports : PR. 2006;58(2):200. 
 
85.  Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, 
arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 
and D2 dopaminergic systems. Journal of Psychopharmacology. 2011;25(1):131-140. 
doi:10.1177/0269881110376688 
  36 
86.  Onaivi ES. Neuropsychobiological Evidence for the Functional Presence and 
Expression of Cannabinoid CB2 Receptors in the Brain. NPS. 2006;54(4):231-246. 
doi:10.1159/000100778 
 
87.  Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-
like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. 
Psychopharmacology. 2008;199(2):223. doi:10.1007/s00213-008-1168-x 
 
88.  Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective 
cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced 
mice. Behavioural Pharmacology. 2005;16(5-6):405. 
 
89.  Haller J, Barna I, Barsvari B, et al. Interactions between environmental 
aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH 
inhibition in rats. Psychopharmacology. 2009;204(4):607-616. doi:10.1007/s00213-009-
1494-7 
 
90.  Zarrindast M-R, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, 
Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like 
behavior: interaction with the opioid system. Behavioural pharmacology. 
2008;19(7):716-723. doi:10.1097/FBP.0b013e3283123c83 
 
91.  Moreira FA, Aguiar DC, Terzian ALB, Guimarães FS, Wotjak CT. Cannabinoid 
type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and 
anxiety-two sides of one coin? Neuroscience. 2012;204:186-192. 
doi:10.1016/j.neuroscience.2011.08.046 
 
92.  Moreira FA. Central side-effects of therapies based on CB1 cannabinoid receptor 
agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin 
Endocrinol Metab. 2009;23(1):133. 
 
93.  Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. High Occurrence of 
Mood and Anxiety Disorders Among Older Adults: The National Comorbidity Survey 
Replication. Arch Gen Psychiatry. 2010;67(5):489-496. 
doi:10.1001/archgenpsychiatry.2010.35 
 
94.  Chorpita BF, Barlow DH. The Development of Anxiety: The Role of Control in 
the Early Environment. Psychological bulletin. 1998;124(1):3-21. doi:10.1037/0033-
2909.124.1.3 
 
95.  Fadok JP, Argilli E, Garelick MG, et al. Activation of Dopamine Neurons Is 
Critical for Aversive Conditioning and Prevention of Generalized Anxiety. Vol 14.; 2011. 
doi:10.1038/nn.2808 
  37 
96.  Opponency Revisited: Competition and Cooperation Between Dopamine and 
Serotonin | Neuropsychopharmacology. https://www.nature.com/articles/npp2010151. 
Accessed March 21, 2019. 
 
97.  Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical 
review of the evidence. Human Psychopharmacology: Clinical and Experimental. 
2009;24(7):515-523. doi:10.1002/hup.1048 
 
98.  Fong M. Assessment and diagnosis of DSM-IV anxiety disorders. Journal of 
counseling and development. 1999;77(2):209. 
 
99.  Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for 
cannabinoid CB 1 receptor antagonists in major depressive disorders. Trends in 
pharmacological sciences. 2005;26(12):609-617. doi:10.1016/j.tips.2005.10.006 
 
100.  García-Gutiérrez MS, Manzanares J. The cannabinoid CB1 receptor is involved in 
the anxiolytic, sedative and amnesic actions of benzodiazepines. Journal of 
psychopharmacology (Oxford, England). 2010;24(5):757-765. 
doi:10.1177/0269881109106910 
 
101.  Central nervous system effects of haloperidol on THC in healthy male volunteers. 
Journal of Psychopharmacology. 2010;24(11):1697-1708. 
doi:10.1177/0269881109358200 
 
102.  Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. 
Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor 
potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139(4):1405-
1415. doi:10.1016/j.neuroscience.2006.02.074 
 
103.  Hebert-Chatelain E, Reguero L, Puente N, et al. Cannabinoid control of brain 
bioenergetics: Exploring the subcellular localization of the CB1 receptor. Molecular 
Metabolism. 2014;3(4):495-504. doi:10.1016/j.molmet.2014.03.007 
 
104.  Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat 
brain. An immunohistochemical study☆. Peptides. 2000;21(11):1735-1742. 
doi:10.1016/S0196-9781(00)00324-7 
 
105.  Eggan SM, Lewis DA. Immunocytochemical Distribution of the Cannabinoid 
CB1 Receptor in the Primate Neocortex: A Regional and Laminar Analysis. Cereb 
Cortex. 2007;17(1):175-191. doi:10.1093/cercor/bhj136 
 
106.  Zarate J, Churruca I, Echevarría E, et al. Immunohistochemical localization of 
CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: 
Effects of chronic fluoxetine treatment. Brain Research. 2008;1236:57-72. 
doi:10.1016/j.brainres.2008.07.100 
  38 
107.  Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C, et al. The endocannabinoid system 
in mental disorders: Evidence from human brain studies. Biochemical Pharmacology. 
2018;157:97-107. doi:10.1016/j.bcp.2018.07.009 
 
108.  Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in 
brain. PNAS. 1990;87(5):1932-1936. 
 
109.  Mátyás F, Urbán GM, Watanabe M, et al. Identification of the sites of 2-
arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at 
both GABAergic and glutamatergic synapses in the ventral tegmental area. 
Neuropharmacology. 2008;54(1):95-107. doi:10.1016/j.neuropharm.2007.05.028 
 
110.  Gong J-P, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: 
Immunohistochemical localization in rat brain. Brain research. 2006;1071(1):10-23. 
doi:10.1016/j.brainres.2005.11.035 
 
111.  Lanciego JL, Barroso-Chinea P, Rico AJ, et al. Expression of the mRNA coding 
the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. Journal of 
Psychopharmacology. 2011;25(1):97-104. doi:10.1177/0269881110367732 
 
112.  Brusco A, Tagliaferro P, Saez T, Onaivi ES. Postsynaptic localization of CB2 
cannabinoid receptors in the rat hippocampus. Synapse. 2008;62(12):944-949. 
doi:10.1002/syn.20569 
 
113.  Suárez J, Llorente R, Romero‐Zerbo SY, et al. Early maternal deprivation induces 
gender-dependent changes on the expression of hippocampal CB1 and CB2 cannabinoid 
receptors of neonatal rats. Hippocampus. 2009;19(7):623-632. doi:10.1002/hipo.20537 
 
114.  Suárez J, Romero‐Zerbo SY, Rivera P, et al. Endocannabinoid system in the adult 
rat circumventricular areas: An immunohistochemical study. Journal of Comparative 
Neurology. 2010;518(15):3065-3085. doi:10.1002/cne.22382 
 
115.  Zhang H-Y, Gao M, Liu Q-R, et al. Cannabinoid CB 2 receptors modulate 
midbrain dopamine neuronal activity and dopamine-related behavior in mice. 
Proceedings of the National Academy of Sciences. 2014;111(46):E5007-E5015. 
doi:10.1073/pnas.1413210111 
 
116.  Ashton JC, Friberg D, Darlington CL, Smith PF. Expression of the cannabinoid 
CB2 receptor in the rat cerebellum: An immunohistochemical study. Neuroscience 
Letters. 2006;396(2):113-116. doi:10.1016/j.neulet.2005.11.038 
 
117.  Baek J-H, Yiwen heng, Darlington CL, Smith PF. Cannabinoid CB2 receptor 
expression in the rat brainstem cochlear and vestibular nuclei. Acta Oto-Laryngologica. 
2008;128(9):961-967. doi:10.1080/00016480701796944 
  39 
118.  Koch M, Habazettl I, Dehghani F, Korf H-W. The rat pineal gland comprises an 
endocannabinoid system. Journal of Pineal Research. 2008;45(4):351-360. 
doi:10.1111/j.1600-079X.2008.00597.x 
 
119.  Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A. Expression of G 
protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell 
lines as revealed by microarray analysis. BMC genomics. 2011;12(1):14-14. 
doi:10.1186/1471-2164-12-14 
 
  40 
APPENDIX A 
TABLES OF CB1 AND CB2 RECEPTOR EXPRESSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  41 
 
Location Cell Type Density Reference 
Olfactory Bulb & 
Tubercle 
Neurons Moderate Cristino et. al 2006102, 
Hebert-Chatelain et. al 
2014103, Moldrich & Wenger 
2000104 
Cerebral Cortex Neurons in layers 
II-III, in upper layer 
V, and in layer VI 
(soma only, no 
axonal 
localization) 
 
 
Layers I & IV 
High 
 
 
Low  
(layer IV overall 
lowest density in 
frontal lobe) 
Eggan & Lewis 2007105, 
Hebert-Chatelain et. al 
2014, Moldrich & Wenger 
2000, Zarate et. al 2008106 
Pre-frontal Cortex Neurons  High Eggan & Lewis 2007, 
Hebert-Chatelain et. al 2014 
Cingulate Cortex Glial cells, neurons Moderate Ibarra-Lecue et. al 2018107, 
Eggan & Lewis 2007, 
Hebert-Chatelain et. al 
2014, Moldrich & Wenger 
2000 
Thalamic Nuclei Neuron & glial 
cells 
Low Cristino et. al 2006, Moldrich 
& Wenger 2000 
Hypothalamus Neurons Low Moldrich & Wenger 2000 
Hippocampus: 
CA1,  CA2 & CA3 
Pyramidal neurons 
& interneurons 
Moderate-High 
(highest in CA1) 
Cristino et. al 2006, Eggan 
& Lewis 2007, Herkenham 
et. al 1990, Moldrich & 
Wenger 2000 
Hippocampus 
CA1  
Interneuron-like 
cells 
High Eggan & Lewis 2007, 
Moldrich & Wenger 2000 
Dentate Gyrus Neurons High Cristino et. al 2006, Eggan 
& Lewis 2007, Moldrich & 
Wenger 2000 
Subiculum Neurons High Eggan & Lewis 2007, 
Moldrich & Wenger 2000 
Entorhinal Cortex Neurons Moderate-High Moldrich & Wenger 2000 
Amygdala Neuron & glial 
cells 
Moderate-High Cristino et. al 2006, Eggan 
& Lewis 2007, Herkenham 
et. al 1990108, Moldrich & 
Wenger 2000 
Caudate-
Putamen/Striatum 
Neurons, DA 
Neurons 
High Herkenham et. al 1990, 
Moldrich & Wenger 2000 
Globus Pallidus 
(GPe & GPi) 
Neurons High Herkenham et. al 1990, 
Moldrich & Wenger 2000 
Substantia Nigra 
PR 
Neurons High Cristino et. al 2006, Eggan 
& Lewis 2007, Moldrich & 
Wenger 2000 
Nucleus 
Accumbens 
 
-- Moderate Eggan & Lewis 2007, 
Moldrich & Wenger 2000 
  42 
Ventral 
Tegmental Area 
DA Neurons (D1, 
D2) 
High Martin et. al 2008109,  
Periaqueductal 
gray, Pons, Area 
Postrema 
-- Low Moldrich & Wenger 2000 
Cerebellum: all 
layers 
Inhibitory 
Interneurons 
High Moldrich & Wenger 2000 
 
Cerebellum: 
Purkinje cells 
Neurons High Herkenham et. al 1990, 
Moldrich & Wenger 2000 
Cerebellum: 
Molecular layer 
Dendrites Moderate Herkenham et. al 1990, 
Moldrich & Wenger 2000 
Cerebellum: 
Granular Layer 
Mossy fibers & 
neuropil 
Moderate Herkenham et. al 1990, 
Moldrich & Wenger 2000 
Olfactory Bulb, 
Piriform Cortex, 
Cingulate Cortex, 
Medial Forebrain 
Bundle and 
Substantia Nigra 
Perivascular glial 
fibers 
Moderate-High Moldrich & Wenger 2000 
 
Table 2 – Localization and Expression of Cannabinoid Receptor 1 in the CNS  
Distribution and expression levels of cannabinoid receptor 1 protein observed in various 
regions throughout the central nervous system. CB1 is expressed widely and in high 
densities making it rather easy to identify when compared to CB2.  
 
 
 
Location Cell Type Reference 
Olfactory Bulb & 
Tubercle 
Neurons Gong et al. 2006110 
Cerebral Cortex Pyramidal-like neurons layers 
III & V 
Gong et al. 2006, Lanciego et. al 
2011111 
Thalamic Nuclei 
 
Neuron & glial cells Gong et al. 2006 
Hippocampus: CA2 & 
CA3 
Pyramidal neurons & 
interneurons 
Brusco et al. 2008112, Gong et al. 
2006 
Hippocampus CA1 & 
CA3 
Interneuron-like cells Lanciego et al. 2011 
Amygdala 
 
Neuron & glial cells Garcia-Gutierrez et al. 201047, 
Gong et al. 2006 
Strata Oriens & 
Radiatum 
Neuropil Suarez et. al 2008, 2009113,114 
Corpus Callosum Glial cells Gong et al. 2006 
Globus Pallidus Neurons Lanciego et al. 2011 
Periaqueductal gray, 
Substantia Nigra 
Neurons Brusco et al. 2008, Gong et al. 
2006 
Ventral Tegmental Area 
 
DA Neurons  Zhang et al. 2014115 
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Cerebellum: Molecular 
Layer 
Parallel varicose fibers and 
neuropil 
Ashton et al. 2006116, Baek et al. 
2008, Gong et al. 2006 
Cerebellum: Purkinje 
cells 
Neurons Baek et al. 2008117, Suarez et al. 
2008, 2009 
Cerebellum: Granular 
Layer 
Mossy fibers & neuropil Baek et al. 2008, Suarez et al. 
2008, 2009 
Pineal Gland Pinealocytes & intrapineal 
nerve fibers 
Koch et al. 2008118 
Retina Inner photoreceptor 
segments, inner nuclear layer, 
ganglion cell layer 
Lopez et al. 2010119 
Nucleus Accumbens 
 
-- Garcia-Gutierrez et al. 2010 
Cingulate Cortex -- Garcia-Gutierrez et al. 2010 
 
Table 3 - Localization of Cannabinoid Receptor 2 in the CNS 
Distribution of cannabinoid receptor 2 throughout regions of the central nervous system 
as determined using immunocytochemical analysis as well as in situ hybridization of 
mRNA transcripts.  This latter method provides much better resolution of cellular 
transcription because of the lack of specificity in commercially available CB2 antibodies 
and the low expression levels of CB2 protein in the CNS. 
